Navigation Links
Venaxis to Provide Third Quarter 2013 Business Update
Date:10/31/2013

CASTLE ROCK, Colo., Oct. 31, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will provide a third quarter business update on Thursday, November 7, 2013, at 8:30 a.m. ET.  The conference call will be hosted by Steve Lundy, Chief Executive Officer; Jeff McGonegal, Chief Financial Officer; and Don Hurd, Senior Vice President and Chief Commercial Officer.

Interested participants and investors may access the conference call by dialing 1 (877) 870-4263 (U.S.), 1 (855) 669-9657 (Canada) or 1 (412) 317-0790 (international).  A live audio webcast will be accessible via the Investor Relations section of the Venaxis™ web site, ir.venaxis.com.  

A telephonic replay of the call will be available for 90 days beginning approximately on hour after the end of the conference call through February 7, 2014.  Access numbers for this replay are 1 (877) 344-7529 (U.S./Canada) and 1 (412) 317-0088 (international); conference ID: 10036520.  The webcast replay will remain available in the Investors Relations section of the Venaxis web site for 90 days.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicitis.  This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appen
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AspenBio Pharma Changes Company Name to Venaxis, Inc.
2. Venaxis to Present at 2013 BIO CEO and Investor Conference
3. Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
4. Venaxis to Present at 25th Annual ROTH Conference
5. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
6. Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors
7. Venaxis to Present at Canaccord Genuity 33rd Annual Growth Conference
8. Venaxis to Present at Three Upcoming Investor Conferences
9. Netsmarts Focus on Innovation to Help Health and Human Service Providers Span the Spectrum of Care in the Healthcare 3.0 Environment
10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
11. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... Diagnostic Device An ophthalmic diagnostic device ... or deficiency in the human visual pathway. Ophthalmic devices ... presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
(Date:7/25/2014)...  Semler Scientific, Inc. (Nasdaq: SMLR ... that develops patented products that assist healthcare providers ... reported financial results for the second quarter and ... "The second quarter of 2014 continued to ... , M.D., chief executive officer of Semler.  "We ...
(Date:7/25/2014)...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... report second quarter 2014 financial results before the NASDAQ ... That same day, Arena will host a conference call ... Pacific Time). The conference call may ... 914.495.8552 for international callers. Please specify to the operator ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... Results,published this week in The Lancet show that ... 6, 11,16, 18) Recombinant Vaccine) was 100 percent ... by HPV,types 16 and 18, two types strongly ... observed in women who were not,infected with HPV ...
... at 9th International Symposium on,Myelodysplastic Syndromes, TAMPA, Fla., ... a pivotal Phase II trial evaluating Revlimid in ... syndromes (MDS),were presented today by Dr. Alan List, ... Institute, at the 9th International,Symposium on MDS currently ...
Cached Medicine Technology:Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 2Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 3Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 5Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 6Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 7Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 8Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 10Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 11Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 12Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 13Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 14Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 15Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 16Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 17Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 18Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 19Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 20Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 21Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 22Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 23Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 24Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 25Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 26Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 27Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 28Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 29Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 30Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 31Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 32Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 2Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 3
(Date:7/25/2014)... UT (PRWEB) July 25, 2014 ... surfaces for the recent Nike National Invitational Tournament ... current United States Junior National Tournament (USJN) ... 25. , The flooring for these prestigious national tournaments ... than 300,000 square feet of playing surface at McCormick ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Florida Hospital and ... two not-for-profit organizations for years to come and make a ... with a $2 million dollar check to provide the support ... investment will enable MOSI to transform the IMAX Dome Theatre ... MOSI has the only IMAX Dome Theatre in the state ...
(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... results of which are published today in Cancer , ... 55 and 74 who had an abnormal finding on a ... reduced quality of life than did those who were screened ... as a surprise to the researchers. “We expected that participants ...
(Date:7/25/2014)... July 25, 2014 This is ... state of the Galactooligosaccharides (GOS) industry in ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
Breaking Medicine News(10 mins):Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3
... Document Management,(Tricom), a company specializing in the electronic ... clientele, has announced the acquisition of,Pacific Data Centers, ... services to its clients so that they can ... 1967, PDC utilizes the latest technological advances and,state-of-the-art ...
... U.S. Senate to vote soon on legislation that ... Mississippi, WASHINGTON, July 9 Seniors across,Mississippi ... Medicare,Advantage program in legislation being considered in the ... million from the Medicare Advantage,program in Mississippi alone ...
... McCain Wrong on Veterans Health Care, WASHINGTON, ... Government Employees (AFGE) launched a nationwide radio ad,campaign ... health care. In addition to the radio ads, ... Affairs, launched a Web site, http://www.fundtheva.com, and ...
... Rochester Medical Center (URMC) will collaborate with the U.S. ... repository of data that will aid academic and industry ... addition to helping researchers understand many cardiac problems, the ... detect drugs that can have dangerous effects on the ...
... DALLAS, July 9 The Maltese healthcare system,will ... leaders from around the,world learn how the island ... model for the European Union to follow. Affiliated,Computer ... discuss the future,of healthcare and information technology while ...
... behavior threaten safety, quality, OAKBROOK TERRACE, Ill., July ... can test the limits of,civility in the workplace. A ... rude language and hostile behavior among health care,professionals goes ... safety and the overall quality of care., Intimidating ...
Cached Medicine News:Health News:Tricom Document Management Expands Onshore Services with Acquisition of Pacific Data Centers, Inc. 2Health News:Mississippi Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Union Representing VA Workers Launch Nationwide Radio Campaign, Web Site and Viral Videos for Full VA Funding 2Health News:URMC, FDA to collaborate on national data repository for heart research 2Health News:URMC, FDA to collaborate on national data repository for heart research 3Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 2Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 3Health News:Joint Commission Alert: Stop Bad Behavior Among Health Care Professionals 2Health News:Joint Commission Alert: Stop Bad Behavior Among Health Care Professionals 3
Ergotec Vetriretinal Instrument System. 2 mm pointed tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
Angled shafts with 11 mm long tips. Jaws have longitudinal meshing serrations. Slide lock and serrated handle with polished finish....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Serrated tips, straight platforms....
Medicine Products: